Peter A Humphrey
Overview
Explore the profile of Peter A Humphrey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
190
Citations
7233
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen F, Esmaili R, Khajir G, Zeevi T, Gross M, Leapman M, et al.
Eur Urol Oncol
. 2025 Feb;
PMID: 39924390
Background And Objective: Conventional core needle biopsy for prostate cancer diagnosis can lead to diagnostic uncertainty and complications, prompting exploration of alternative risk assessment approaches that use clinical and imaging...
2.
Tripathi A, Tangen C, Plets M, Li X, Tretiakova M, Humphrey P, et al.
BJU Int
. 2024 Jul;
134(4):596-601.
PMID: 39014969
Objective: To evaluate the clinical significance of subtyping (type 1 vs 2) of papillary renal cell carcinoma (PRCC) in patients treated with targeted therapy, as well as the concordance, sensitivity...
3.
Adeniran A, Shuch B, Humphrey P
Am J Surg Pathol
. 2024 May;
48(7):e65-e88.
PMID: 38736105
Renal cell carcinoma (RCC) with sarcomatoid and rhabdoid morphologies has an aggressive biological behavior and a typically poor prognosis. The current 2022 WHO classification of renal tumors does not include...
4.
Riddle N, Parkash V, Guo C, Shen S, Perincheri S, Ramirez A, et al.
Arch Pathol Lab Med
. 2023 Nov;
148(8):952-964.
PMID: 38031818
Context.—: Urinary and Male Genital Tumours is the 8th volume of the World Health Organization Classification of Tumours series, 5th edition. Released in hard copy in September 2022, it presents...
5.
Lerner G, Tang H, Singh K, Golestani R, St Claire S, Humphrey P, et al.
Clin Breast Cancer
. 2022 Dec;
23(2):199-210.
PMID: 36577560
Background: Carcinoma with apocrine differentiation (AC) is a subtype of breast carcinoma with apocrine features in >90% of the tumor. Molecular studies demonstrate AC has high expression of androgen receptor...
6.
Paulson N, Zeevi T, Papademetris M, Leapman M, Onofrey J, Sprenkle P, et al.
JCO Clin Cancer Inform
. 2022 Sep;
6:e2200016.
PMID: 36179281
Purpose: There is ongoing clinical need to improve estimates of disease outcome in prostate cancer. Machine learning (ML) approaches to pathologic diagnosis and prognosis are a promising and increasingly used...
7.
Bulten W, Kartasalo K, Chen P, Strom P, Pinckaers H, Nagpal K, et al.
Nat Med
. 2022 Jan;
28(1):154-163.
PMID: 35027755
Artificial intelligence (AI) has shown promise for diagnosing prostate cancer in biopsies. However, results have been limited to individual studies, lacking validation in multinational settings. Competitions have been shown to...
8.
Martin D, Lee J, Liu Q, Galiana G, Sprenkle P, Humphrey P, et al.
Nanomedicine
. 2021 Nov;
40:102477.
PMID: 34740868
Magnetic resonance is a key imaging tool for the detection of prostate cancer; however, better tools focusing on cancer specificity are required to distinguish benign from cancerous regions. We found...
9.
Shah R, Cai Q, Aron M, Berney D, Cheville J, Deng F, et al.
Am J Cancer Res
. 2021 Sep;
11(8):3990-4001.
PMID: 34522463
Accurate diagnosis of cribriform Gleason pattern 4 (CrP4) prostate adenocarcinoma (PCa) is important due to its independent association with adverse clinical outcomes and as a growing body of evidence suggests...
10.
Yang C, Shuch B, Kluger H, Serrano M, Kibel A, Humphrey P, et al.
Am J Clin Pathol
. 2021 Aug;
156(4):550-558.
PMID: 34424955
Objectives: Tumor size has long been used in the management decision-making of patients with renal masses. Active surveillance had recently gained traction in selected patients with tumor size of 4 ...